Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia

European Journal of Clinical Pharmacology

Volumn 69, Issue 4, 2013, Pages 813-823

  Giles, Francis J ^a   Yin, Ophelia Q P ^b   Sallas, William M ^b   Le Coutre, Philipp D ^c   Woodman, Richard C ^b   Ottmann, Oliver G ^d   Baccarani, Michele ^e   Kantarjian, Hagop M ^f  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f UNIVERSITY OF TEXAS   (United States)

Author keywords

Chronic myeloid leukemia; Imatinib; Intolerance; Nilotinib; Pharmacokinetic; Resistance

Indexed keywords

BILIRUBIN; IMATINIB; NILOTINIB; TRIACYLGLYCEROL LIPASE;

ADOLESCENT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NONLINEAR SYSTEM; OPEN STUDY; PATIENT COMPLIANCE; PHARMACOKINETICS; PRIORITY JOURNAL; PROGNOSIS; STEADY STATE TROUGH CONCENTRATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; BIOLOGICAL AVAILABILITY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PIPERAZINES; PYRIMIDINES; YOUNG ADULT;

EID: 84876712497     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1385-4     Document Type: Article

References (24)

1. Tasigna [package insert] (2010) Novartis Pharmaceuticals Corp, East Hanover, NJ
2. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz JA, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, Blakesley R, Baccarani M, Cortes J, le Coutre PD (2011) Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results. Blood 117:1141-1145
3. le Coutre PD, Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R, Shou Y, Gallagher NJ, Baccarani M, Cortes J, Kantarjian HM (2012) Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 26:1189-1194
4. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542-2551
5. Tanaka C, Yin OQ, Sethuraman V, Smith T, Wang X, Grouss K, Kantarjian H, Giles F, Ottmann OG, Galitz L, Schran H (2010) Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 87:197-203
6. Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, Kantarjian HM, le Coutre PD (2012) Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph + chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol 68:723-733
7. Yin OQ, Gallagher N, Li A, Zhou W, Harrell R, Schran H (2010) Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 50:188-194
8. Singer JB, Shou Y, Giles F, Kantarjian HM, Hsu Y, Robeva AS, Rae P, Weitzman A, Meyer JM, Dugan M, Ottmann OG (2007) UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 21:2311-2315
9. Beal SL, Sheiner LB (1998) NONMEM users' guide. University of California at San Francisco, San Francisco
10. Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications. Lippincott, Williams, and Wilkins, Philadelphia
11. Fullmer A, Kantarjian H, Cortes J, Jabbour E (2010) Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia. Expert Opin Pharmacother 11:3065-3072
12. Kantarjian HM, Jabbour E, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Wang J, Woodman RC, Baccarani M, le Coutre PD, Cortes J (2009) Prognostic factors for progression-free survival in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib based on 24 month data. Blood 114:1278-1279 [abstract 3298]
13. Burton ME, Shaw LM, Schentag JJ, Evans WE (2006) Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring. Lippincott, Williams, and Wilkins, Philadelphia
14. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F (1984) Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63:789-799
15. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90:850-858
16. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE (2002) Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 8:2177-2187
17. Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A (2009) Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 27:4204-4210
18. Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, Mestan J, Trappe J, Wartmann M, Fabbro D (2010) Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 1804:445-453
19. Fujita KI, Sugiyama M, Akiyama Y, Ando Y, Sasaki Y (2011) The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1. Cancer Chemother Pharmacol 67:237-241
20. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG (2005) In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 33:1729-1739
21. Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P, Feinberg J, Sherman KE (2001) Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A 98:12671-12676
22. Xu CF, Reck BH, Xue Z, Huang L, Baker KL, Chen M, Chen EP, Ellens HE, Mooser VE, Cardon LR, Spraggs CF, Pandite L (2010) Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer 102:1371-1377
23. Meza-Junco J, Chu QS, Christensen O, Rajagopalan P, Das S, Stefanyschyn R, Sawyer MB (2009) UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer Chemother Pharmacol 65:1-4
24. Spraggs C, Budde L, Briley L, Bing N, Newstat B, Rappold E (2009) Hyperbilirubinemia in lapatinib-treated patients is associated with Gilbert's syndrome UGT1A1 polymorphism. Cancer Res 69:1112